Angiographic findings of the multicenter Randomized Study With the Sirolimus-Eluting Bx Velocity Balloon-Expandable Stent (RAVEL): sirolimus-eluting stents inhibit restenosis irrespective of the vessel size
- E. Regar
- P. W. Serruys
- C. Bode
- C. Holubarsch
- J. L. Guermonprez
- W. Wijns
- A. Bartorelli
- C. Constantini
- M. Degertekin
- K. Tanabe
- C. Disco
- E. Wuelfert
- M. C. Morice
Publication date
October 2002
DOI Publisher
Ovid Technologies (Wolters Kluwer Health)Abstract
Restenosis remains the major limitation of coronary catheter-based intervention. In small vessels, the amount of neointimal tissue is disproportionately greater than the vessel caliber, resulting in higher restenosis rates. In the Randomized Study With the Sirolimus-Eluting Bx Velocity Balloon-Expandable Stent (RAVEL) trial, approximately 40% of the vessels were small (<2.5 mm). The present study evaluates the relationship between angiographic outcome and vessel diameter for sirolimus-eluting stents
Add to ORKG